Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs

Review

Accepted on 20 Oct 2025

Mechanistic insights into the antitumor effects of Astragaloside IV and Astragalus polysaccharide in digestive system cancers

in Pharmacology of Anti-Cancer Drugs

Qingxin Shang
Zhenhua Cui

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1691011

Original Research

Accepted on 20 Oct 2025

Selective anti-cancer effects of cannabidiol and Δ9-Tetrahydrocannabinol via PI3K/AKT/mTOR inhibition and PTEN restoration in ovarian cancer cells

in Pharmacology of Anti-Cancer Drugs

Siyao Tong
Watcharin Loilome
Nisana Namwat
Poramate Klanrit
Arporn Wangwiwatsin
Zar Zar Win
Preeya Koyabuth
Bandit Chumworathayi

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1693129

Systematic Review

Accepted on 20 Oct 2025

Astragalus Polysaccharides Combined with Radiochemotherapy for Cervical Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Studies

in Pharmacology of Anti-Cancer Drugs

Tao Sun
Ruping Zhao
Yaling Zhang
Dongdong Li
Xishen Shan
Xiaoyu Tang
Yuling Zheng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1699902

Mini Review

Accepted on 20 Oct 2025

PLGA-based nanoparticles in colorectal cancer immunotherapy: current concepts and future perspectives

in Pharmacology of Anti-Cancer Drugs

YuHan Wang
Peng Huang
Chun Li
ShengJin Tu
Hua Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1714460

Review

Published on 20 Oct 2025

Epigenetic mechanisms of drug resistance in acute myeloid leukemia: advances in small-molecule targeted therapy

in Pharmacology of Anti-Cancer Drugs

Jialing Tang
Xibo Ye
Zhangyang Xu
Tianjiao Min
Zherun Tian
Li Ma
Ying He
Beier Jiang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1672524

761 views

Original Research

Accepted on 17 Oct 2025

Multilocus Inherited Neoplasia Allele Syndrome (MINAS) in a Turkish Cohort: Molecular Insights and Clinical Relevance for Precision Oncology

in Pharmacology of Anti-Cancer Drugs

Taha Bahsi
Serhat Seyhan
Kaan Helvaci
Umut Demirci
Irem Bilge Tekin
Selami Bayram
Mehmet Akif Ozturk
Fatih Aydogan
Serkan Keskin
Kezban Pilanci

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1672774

201 views

Original Research

Published on 17 Oct 2025

Alkaloid-driven multi-target synergy of Tripterygium wilfordii polyglycosides overcomes cisplatin resistance in ovarian cancer by coordinated inhibition of PTPN11/EGFR/JAK signaling

in Pharmacology of Anti-Cancer Drugs

Bing Lin
Minxin Zhang
Ying Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1686526

442 views

Case Report

Published on 17 Oct 2025

Cardiotoxicity related to intrapericardial infusion of bevacizumab in the treatment of lung cancer-mediated malignant pericardial effusion: a case report

in Pharmacology of Anti-Cancer Drugs

Shilong Wu
Yanjun Lu
Chenyang Xu
Huafeng Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1573297

284 views

Review

Published on 17 Oct 2025

Clinically approved immunotoxins targeting hematological cancers: “the best of both worlds”

in Pharmacology of Anti-Cancer Drugs

Yasmine Rashad
Eckhard U. Alt
Reza Izadpanah
Xuebin Qin
Stephen E. Braun

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1569502

535 views

Review

Published on 16 Oct 2025

Novel strategies for nanovaccine application in breast cancer treatment

in Pharmacology of Anti-Cancer Drugs

Huan Liu
Ning Ma

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1691991

390 views

Original Research

Published on 16 Oct 2025

BYS10, a novel selective RET inhibitor, exhibits potent antitumor activity in preclinical models

in Pharmacology of Anti-Cancer Drugs

Fei Qin
Yiman Chen
Jinhai Deng
Ruizhi Guo
Zhoufan Xie
Zhibo Luo
Lin Wang
Tianbai Huang
Jiaji Zhao
Jiansong Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1670140

417 views

Case Report

Accepted on 15 Oct 2025

HGF and NF1 mutations as putative bypass mechanisms of MET inhibitor resistance in hepatocellular carcinoma: A case study

in Pharmacology of Anti-Cancer Drugs

Zhitao Chen
Shan Luo
Yangjun Gu
Qiyong Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1659463

226 views

Original Research

Published on 15 Oct 2025

Glutaredoxin2 reduces age-associated B cell differentiation through maintaining redox homeostasis

in Pharmacology of Anti-Cancer Drugs

Yuan Jiang
Chunli Sun
Qilin He
Shujun Liu
Shihao Tian
Yan Zhang
Yatao Du
Fubin Li
Huihui Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1593816

656 views

Review

Published on 15 Oct 2025

Targeting MDM2, RAS, and PCNA for cancer targeted therapy: pan-cancer approaches vs. cancer-specific strategies

in Pharmacology of Anti-Cancer Drugs

Wei Wang
Abigail Alley
Na Sun
Meheret Tadesse
Xinshi Wang
Ruiwen Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1663766

762 views

Review

Published on 15 Oct 2025

Iron, copper and disulfide dysregulation: molecular crossroads of metabolic cell death in melanoma progression

in Pharmacology of Anti-Cancer Drugs

Xinge Li
Yan Gao
Zhiyao Xing
Zichuan Liu
Xiangyang Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1685331

306 views

Original Research

Accepted on 14 Oct 2025

A galactoarabinan contained glycoprotein isolated from the fruits of Lycium barbarum reverses the tumor-associated macrophage phenotype

in Pharmacology of Anti-Cancer Drugs

Wang Bo
Bowen Lu
Junqiang Lv
Caixia Dong
Changcai' Bai

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1593407

109 views